Corona Remedies Sees Strong FY26 Growth, Acquires Wokadine, Proposes ₹10 Dividend

Corona Remedies announced robust financial results for fiscal year 2026, reporting consolidated revenue of ₹1,403.18 crore, a 17.3% increase from the previous year. Profit After Tax (PAT) surged 33.4% to ₹185.12 crore.

Financial Highlights for FY26 and Q4

The company's Board of Directors approved the audited financial results for the fiscal year and fourth quarter ended March 31, 2026.

Full-year FY26 consolidated revenue reached ₹1,403.18 crore, up 17.3% year-on-year. PAT climbed 33.4% to ₹185.12 crore.

For the fourth quarter of FY26 (Q4FY26), revenue grew 20.2% year-on-year to ₹353.09 crore, while PAT increased 43.7% to ₹45.33 crore.

The company noted an exceptional item related to the statutory impact of new Labour Codes, which affected pre-tax profit by ₹19.10 crore for FY26.

Strategic Significance of Performance and Acquisition

The strong financial results reflect Corona Remedies' solid operational performance and effective growth strategies. The proposed dividend offers shareholders a direct return on investment.

The acquisition of WOKADINE marks a strategic move to enter new therapeutic areas, aiming to boost future revenue and market share in a competitive landscape.

Wokadine Acquisition Details

Corona Remedies acquired WOKADINE for ₹648 crore, a transaction funded entirely by internal cash.

This acquisition enables the company to enter the Povidone Iodine market, diversifying its product portfolio and strengthening its market position.

Key Updates: Shareholder Returns and Operations

Shareholders are set to benefit from a proposed final dividend of ₹10 per equity share for FY26.

The WOKADINE acquisition expands the company's market reach and product offerings.

New auditors have been appointed for financial oversight in the coming fiscal years.

Additionally, Dr. Kirtikumar Mehta's re-appointment as Chairman and Non-Executive Director is proposed, pending shareholder approval.

Potential Risks

The statutory impact of new Labour Codes, recorded as an exceptional item of ₹19.10 crore pre-tax for FY26, needs monitoring for its accounting implications.

Performance vs. Peers

Companies like Cipla and Dr. Reddy's Laboratories reported FY26 revenue growth in the 8-10% range, with PAT growth around 10-15%. Corona Remedies' FY26 performance of 17.3% revenue growth and 33.4% PAT growth stands out compared to these peers.

Looking Ahead

Investors will track shareholder approval for the proposed final dividend of ₹10 per equity share.

The successful integration of the WOKADINE business into Corona Remedies' operations is also key.

The finalization of accounting treatments for the New Labour Codes and their ongoing impact will be monitored.

The commencement of services by the newly appointed auditors is another point to watch.